iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately positive: Six brokerages rate iRadimed “Moderate Buy,” with three buys, one strong buy and two holds. The average 12-month price target is $120, compared with the stock’s opening price of $86.66.
• Recent results exceeded expectations: iRadimed reported quarterly EPS of $0.46 versus the $0.44 consensus estimate and revenue of $20.47 million versus $20.35 million expected. The company projects fiscal 2026 EPS of $2.09–$2.24.
• Ownership and trading activity remain notable: Institutional investors own 92.34% of the shares, while insiders hold 34.60%; director Monty K. Allen recently sold 1,419 shares. The company also pays a quarterly dividend of $0.20, implying a 0.9% annual yield.

Shares of iRadimed Corporation (NASDAQ:IRMD - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $120.00.

A number of research firms recently issued reports on IRMD. Weiss Ratings upgraded iRadimed from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, September 9th. Needham & Company LLC began coverage on shares of iRadimed in a report on Tuesday, September 22nd. They issued a "hold" rating on the stock. Finally, Wall Street Zen lowered shares of iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th.

Insider Buying and Selling

In other news, Director Monty K. Allen sold 1,419 shares of the business's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the transaction, the director directly owned 19,581 shares in the company, valued at $1,691,994.21. The trade was a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 34.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On iRadimed

Several large investors have recently added to or reduced their stakes in IRMD. Integrated Wealth Concepts LLC bought a new position in iRadimed in the 2nd quarter worth about $28,000. IFP Advisors Inc grew its holdings in shares of iRadimed by 264.7% during the second quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider's stock worth $54,000 after purchasing an additional 413 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of iRadimed in the fourth quarter worth approximately $85,000. Inspire Investing LLC bought a new position in shares of iRadimed in the first quarter worth approximately $107,000. Finally, State of Wyoming purchased a new stake in iRadimed in the second quarter valued at approximately $130,000. Institutional investors own 92.34% of the company's stock.

iRadimed Stock Performance

Shares of iRadimed stock opened at $86.66 on Tuesday. The stock has a market capitalization of $1.11 billion, a P/E ratio of 48.41 and a beta of 0.89. iRadimed has a 52-week low of $67.84 and a 52-week high of $107.90. The stock's 50-day simple moving average is $87.85 and its 200 day simple moving average is $91.61.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The firm had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities research analysts forecast that iRadimed will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a $0.20 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed's dividend payout ratio is currently 44.69%.

About iRadimed

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on equipment that enables clinicians to provide continuous care and monitor patients safely while they are undergoing MRI procedures, where conventional medical devices may pose safety or compatibility challenges.

Its product portfolio includes the MRidium MRI-compatible infusion pump systems, which are designed to deliver intravenous medications and fluids during MRI examinations, as well as MRI-compatible patient monitoring systems and related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.